{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:22:47Z","timestamp":1787026967165,"version":"build-2736575974"},"reference-count":20,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,10,14]],"date-time":"2020-10-14T00:00:00Z","timestamp":1602633600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"DOI":"10.3389\/fonc.2020.593461","type":"journal-article","created":{"date-parts":[[2020,10,14]],"date-time":"2020-10-14T01:57:47Z","timestamp":1602640667000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":15,"title":["Ocular Side Effects of EGFR-Inhibitor ABT-414 in Recurrent Glioblastoma: A Long-Term Safety Study"],"prefix":"10.3389","volume":"10","author":[{"given":"Raffaele","family":"Parrozzani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Lombardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edoardo","family":"Midena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Londei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Padovan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Marchione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Caccese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Midena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vittorina","family":"Zagonel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa","family":"Frizziero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,10,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"299","DOI":"10.3322\/caac.21613","article-title":"Management of glioblastoma: State of the art and future directions","volume":"70","author":"Tan","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noy091","article-title":"Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial","volume":"21","author":"Lassman","year":"2019","journal-title":"Neuro Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noz222","article-title":"INTELLANCE 2\/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma","volume":"22","author":"Van Den Bent","year":"2020","journal-title":"Neuro Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2020.100795","article-title":"Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer","volume":"13","author":"Roviello","year":"2020","journal-title":"Transl Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11121826","article-title":"Molecular Targeting Therapy against EGFR Family in Breast Cancer: Progress and Future Potentials","volume":"11","author":"Maennling","year":"2019","journal-title":"Cancers (Basel)"},{"key":"B6","first-page":"81","article-title":"Mebendazole in simultaneous combination with dexamethasone-(C21-phosphoramidate)-[anti-EGFR] generated utilizing a novel synthesis regimen: dual anti-neoplastic cytotoxicity against pulmonary adenocarcinoma (A549)","volume":"13","author":"Coyne","year":"2019","journal-title":"J Exp Ther Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-14-0820","article-title":"Characterization of ABT-806, a humanized tumor-specific anti-EGFR monoclonal antibody","volume":"14","author":"Reilly","year":"2015","journal-title":"Mol Cancer Ther"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-15-0901","article-title":"ABT-414, an antibody-drug conjugate targeting a tumor-selective EGFR epitope","volume":"15","author":"Phillips","year":"2016","journal-title":"Mol Cancer Ther"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1006\/exer.2000.0979","article-title":"The Epidermal Growth Factor Receptor (EGFR): Role in Corneal Wound Healing and Homeostasis","volume":"72","author":"Nakamura","year":"2001","journal-title":"Exp Eye Res"},{"key":"B10","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1089\/jop.2015.0064","article-title":"Ocular Adverse Events Associated with Antibody-Drug Conjugates in Human Clinical Trials","volume":"31","author":"Eaton","year":"2015","journal-title":"J Ocul Pharmacol Ther"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/now257","article-title":"Efficacy and safety results of ABT-414 in combination with radiation and temozolomide in newly diagnosed glioblastoma","volume":"19","author":"Reardon","year":"2017","journal-title":"Neuro Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nox202","article-title":"Safety, pharmacokinetics, and antitumor response of depatuxizumab mafodotin as monotherapyor in combination with temozolomide in patients with glioblastoma","volume":"20","author":"Gan","year":"2018","journal-title":"Neuro Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/sj.eye.6701630","article-title":"Ocular findings in patients with solid tumours treated with the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (\u2018Iressa\u2019, ZD1839) in Phase I and II clinical trials","volume":"19","author":"Tullo","year":"2005","journal-title":"Eye"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3341\/kjo.2011.25.5.355","article-title":"Vortex keratopathy in a patient receiving vandetanib for non-small cell lung cancer","volume":"25","author":"Ahn","year":"2011","journal-title":"Korean J Ophthalmol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1177\/1758835920907543","article-title":"Corneal side effects induced by EGFR- inhibitor antibody\u2013drug conjugate ABT-414 in patients with recurrent glioblastoma: a prospective clinical and confocal microscopy study","volume":"27","author":"Parrozzani","year":"2020","journal-title":"Ther Adv Med Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-016-0507-6","article-title":"Modified Criteria for Radiographic Response Assessment in Glioblastoma Clinical Trials","volume":"14","author":"Ellingson","year":"2017","journal-title":"Neurotherapeutics"},{"key":"B17","volume-title":"Early treatment diabetic retinopathy study (ETDRS). Manual of operations. Chapter 12","year":""},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/S0039-6257(00)00201-0","article-title":"Diagnosis of dry eye","volume":"45","author":"Bron","year":"2001","journal-title":"Surv Ophthalmol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31304","article-title":"Efficacy and safety results of depatuxizumab mafodotin (ABT-414) in patients with advanced solid tumors likely to overexpress epidermal growth factor receptor","volume":"124","author":"Goss","year":"2018","journal-title":"Cancer"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1159\/000494713","article-title":"Corneal Toxicity Induced by ABT-414 Therapy for Glioblastoma Multiforme: A Case Report","volume":"9","author":"Eshraghi","year":"2018","journal-title":"Case Rep Ophthalmol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2020.593461\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,14]],"date-time":"2020-10-14T01:57:49Z","timestamp":1602640669000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2020.593461\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,14]]},"references-count":20,"alternative-id":["10.3389\/fonc.2020.593461"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2020.593461","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,14]]},"article-number":"593461"}}